VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NRC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
NRCNational Research Corporation
$22.77$513M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

NRC logoNational Research Corporation(NRC)Earnings, Financials & Key Ratios

NRC•NASDAQ
$22.77
43.8× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryHealthcare ITSub-IndustryHealthcare Data, Analytics and AI
AboutNational Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.Show more
  • Revenue$137M-4.0%
  • EBITDA$30M-26.7%
  • Net Income$12M-53.2%
  • EPS (Diluted)0.52-50.0%
  • Gross Margin56.33%-6.4%
  • EBITDA Margin21.99%-23.7%
  • Operating Margin16.44%-33.2%
  • Net Margin8.44%-51.3%
  • ROE51.24%-17.0%

NRC Price & Volume

National Research Corporation (NRC) stock price & volume — 10-year historical chart

Loading chart...

Structural Margin Compression Masks Solvency Risk Profile

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Strained
Financial:Vulnerable
Cash Flow:Deteriorating
Primary Risk:Competitive Disintermediation Risk

Key Thesis Takeaways

  • National Research Corporation faces a challenging outlook characterized by persistent revenue contraction and significant margin erosion, with operating margins falling from 30.8% in 2023Q4 to 16.0% in 2026Q1.
  • The company's reliance on debt to fund shareholder returns has resulted in a precarious debt-to-equity ratio of 5.78, raising concerns regarding long-term capital structure sustainability.
  • Furthermore, the threat of competitive disintermediation from EHR giants suggests that the firm's $66.2M goodwill balance may be subject to future impairment risks.

Verdict Logic

the company's deteriorating solvency profile, highlighted by a debt-to-equity ratio of 5.78 and a current ratio of 0.52, suggests significant risk to equity holders.

NRC Growth Metrics

National Research Corporation (NRC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years2.99%
5 Years0.61%
3 Years-3.22%
TTM-1.88%

Profit CAGR

10 Years-4.09%
5 Years-20.81%
3 Years-28.55%
TTM-62.68%

EPS CAGR

10 Years2.41%
5 Years-18.54%
3 Years-25.74%
TTM-61.39%

Return on Capital

10 Years42.65%
5 Years38.95%
3 Years35.12%
Last Year23.18%

NRC Recent Earnings

National Research Corporation (NRC) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 0/12 qtrs (0%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
Apr 28, 2026
Metric
Actual
Est
EPS
$0.21
—
Rev
$35M
—
Q1 2026
Feb 3, 2026
Metric
Actual
Est
EPS
$0.16
—
Rev
$35M
—
Q4 2025
Oct 27, 2025
Metric
Actual
Est
EPS
$0.23
—
Rev
$35M
—
Q3 2025
Jul 28, 2025
Metric
Actual
Est
EPS
$0.28
—
Rev
$34M
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 28, 2026
$0.21
$35M
Q1 2026Feb 3, 2026
$0.16
$35M
Q4 2025Oct 27, 2025
$0.23
$35M
Q3 2025Jul 28, 2025
$0.28
$34M
Based on last 12 quarters of dataView full earnings history →

Latest NRC News

Recent stock market news and headlines for National Research Corporation (NRC)

GuruFocus·Jun 26, 2026
Constellation Seeks License Renewals for Two New York Units Through 2049

Constellation (Nasdaq: CEG) has filed license renewal applications with the Nuclear Regulatory Commission (NRC) to extend the operations of Ginna Clean Energy

GlobeNewsWire·Jun 25, 2026
NANO Nuclear's KRONOS MMR™ Program Advances as U.S. NRC Initiates Formal Review Activities with University of Illinois Urbana-Champaign and NANO Nuclear Energy

Meeting with NRC kicks off review activities and marks continued regulatory progress following acceptance of the KRONOS MMR ™ Construction Permit Application and supports previously disclosed expectations for initial construction activities to begin in the second half of 2027 New York, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, today announced continued progress in the U.S. Nuclear Regulatory Commission's (“NRC”) review of the Construction Permit Application (“CPA”) for deployment of NANO Nuclear's KRONOS MMR ™ Energy System at the University of Illinois Urbana-Champaign (“U.

Newsfile Corp·Jun 25, 2026
NANO Nuclear's KRONOS MMR(TM) Program Advances as U.S. NRC Initiates Formal Review Activities with University of Illinois Urbana-Champaign and NANO Nuclear Energy

Meeting with NRC kicks off review activities and marks continued regulatory progress following acceptance of the KRONOS MMR(TM) Construction Permit Application and supports previously disclosed expectations for initial construction activities to begin in the second half of 2027 New York, New York--(Newsfile Corp. - June 25, 2026) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, today announced continued progress in the U.S. Nuclear Regulatory Commission's ("NRC") review of the Construction Permit Application ("CPA") for deployment of NANO Nuclear's KRONOS MMR™ Energy System at the University of Illinois Urbana-Champaign ("U. of I."). On June 23, 2026, the NRC publicly announced that it had met with representatives from U.

PRNewsWire·Jun 24, 2026
AtkinsRéalis submits Notice of Intent to U.S. Nuclear Regulatory Commission for CANDU® reactor licensing

Company begins formal regulatory engagement to bring large-scale nuclear technology to U.S. market amid surging power demand MONTREAL, June 24, 2026 /PRNewswire/ - AtkinsRéalis Group Inc. (TSX: ATRL), a world-class engineering services and nuclear company with offices around the world, announced that it has formally submitted a Notice of Intent to the U.S. Nuclear Regulatory Commission (NRC) to begin the licensing process for its CANDU® reactor technology in the United States. The filing marks the start of formal pre-application engagement with the NRC and represents a key milestone in the Company's strategy to deploy proven large-scale nuclear power in support of significant U.S. electricity demand driven by data centers, artificial intelligence, advanced manufacturing and broader electrification.

Newsfile Corp·Jun 22, 2026
RZOLV Technologies Completes NRC IRAP-Supported R&D Project for Non-Cyanide Gold Extraction Technology

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - RZOLV Technologies Inc. (TSXV: RZL) (OTCQB: RZOLF) (FSE: S711) ("RZOLV" or the "Company") is pleased to announce that its wholly owned operating subsidiary, Innovation Mining Inc. ("Innovation Mining"), has completed its first research and development project supported by the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP"). Innovation Mining received advisory services and funding from NRC IRAP to support a research and development project focused on the Company's proprietary RZOLV™ non-cyanide gold extraction technology.

Peers Comparison

Key metrics vs top competitors for National Research Corporation (NRC)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
NRC logoNRCNational Research CorporationCurrent
$22.77$513.16M43.79-3.96%8.44%51.24%2.15%
SATS logoSATSEchoStar Corporation
$97.96$28.23B-1.94-5.18%-157.17%-243.07%—
FORR logoFORRForrester Research, Inc.
$9.66$185.24M-1.54-8.23%-13.74%-39.22%—
CSGP logoCSGPCoStar Group, Inc.
$29.87$12.66B1799.4018.67%0.74%0.3%—
MORN logoMORNMorningstar, Inc.
$170.96$6.5B19.277.49%16.06%30.01%—
QNST logoQNSTQuinStreet, Inc.
$16.27$934.64M201.6178.27%5.53%23.85%—

Compare NRC vs Peers

National Research Corporation (NRC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SATS

Most directly comparable listed peer for NRC.

Scale Benchmark

vs CSGP

Larger-name benchmark to compare NRC against a more recognizable public peer.

Peer Set

Compare Top 5

vs SATS, FORR, CSGP, MORN

NRC SEC Filings & Documents

National Research Corporation (NRC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 28, 2026·SEC

Material company update

Apr 28, 2026·SEC

Material company update

Apr 20, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 5, 2026·SEC

FY 2025

Mar 17, 2025·SEC

FY 2024

Feb 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 6, 2026·SEC

FY 2025

Nov 7, 2025·SEC

FY 2025

Aug 8, 2025·SEC

Get notified when NRC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NRC Frequently Asked Questions

National Research Corporation (NRC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is National Research Corporation's revenue?

National Research Corporation (NRC) reported $138.6M in revenue for fiscal year 2025. This represents a 1000% increase from $12.6M in 1996.

How fast is National Research Corporation growing?

National Research Corporation (NRC) saw revenue decline by 4.0% over the past year.

Is NRC profitable?

Yes, National Research Corporation (NRC) is profitable, generating $9.0M in net income for fiscal year 2025 (8.4% net margin).

Dividend & Returns
Does NRC pay dividends?

Yes, National Research Corporation (NRC) pays a dividend with a yield of 2.15%. This makes it attractive for income-focused investors.

What is NRC's return on equity?

National Research Corporation (NRC) has a return on equity (ROE) of 51.2%. This is excellent, indicating efficient use of shareholder capital.

What is National Research Corporation's free cash flow?

National Research Corporation (NRC) generated $17.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in NRC back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →